Signos grows foothold in weight-loss wave fueled by GLP-1s with its AI health data tracking
Signos is expanding its AI health data tracking to enhance weight-loss solutions, particularly for users of GLP-1 drugs. The company aims to provide real-time feedback on food choices and metabolic responses to drive behavior change. With a new partnership with Dexcom, Signos is poised to increase its visibility in the growing weight loss market.
- ▪Signos is developing predictive AI features like meal scoring to help users manage glucose levels.
- ▪The service is designed for those using GLP-1 drugs or as a standalone weight loss system.
- ▪Demand for GLP-1 drugs is surging, with estimates suggesting 25 million Americans will be using them by 2030.
- ▪Signos has reported a tenfold increase in both revenue and user base over the last six months.
- ▪The company emphasizes the importance of tracking metabolic inputs and responses for effective weight management.
Opening excerpt (first ~120 words) tap to expand
The fresh funding will also go to expanding its predictive AI features, like meal scoring, where a user's data is used to warn them about whether a specific food could spike their glucose levels before they eat it.Fouladgar-Mercer said the real opportunity with AI is translating biology into "practical guidance people can actually use.""So you can take a photo of the food and the AI will detect the entity and figure out the macros and all of that, and also the activities, but really it's how do you take that and determine how your body responds in real time to give you that feedback to help drive behavior change," he said.The service is meant either for those who want to complement their GLP-1 drug treatments or as a standalone weight loss system, Fouladgar-Mercer said.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at CNBC — Tech.
Discussion
0 commentsMore from CNBC — Tech
